CoChat

Increased expression of TREM 2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer's disease

Open access
Casati, M., Ferri, E., Gussago, C., Mazzola, P., Abbate, C., Bellelli, G., Mari, D., Cesari, M., Arosio, B. · 2018 · European Journal of Neurology
Cited by 66

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background and purpose: Neuroinflammation plays a role in the aetiopathogenesis of Alzheimer's disease (AD). Triggering receptor expressed on myeloid cells 2 (TREM 2), a cell surface receptor of the immunoglobulin superfamily, seems to have protective anti‐inflammatory activity in AD. Methods: Triggering receptor expressed on myeloid cells 2 expression was analysed in peripheral blood mononuclear cells from healthy subjects (CT) and from patients with either AD or mild cognitive impairment (MCI). MCI patients were re‐evaluated at a 2‐year follow‐up to investigate their progression to AD (MCI‐AD) or lack thereof (MCI‐MCI). Results: Triggering receptor expressed on myeloid cells 2 gene expression was higher in AD than CT patients, but was highest in MCI. At recruitment TREM 2 levels were higher in MCI‐AD than in MCI‐MCI, and in MCI‐AD were higher initially than at follow‐up. TREM 2 displayed a moderate degree of sensitivity and specificity for identifying MCI‐AD in all MCI patients. Our data showed higher TREM 2 levels in allele ε4 of apolipoprotein E (ApoE ε4) carriers than non‐carriers in MCI and particularly in MCI‐AD. Conclusions: These data seem to confirm the protective role of TREM 2 in the pre‐clinical stage of AD. Upregulation of TREM 2 in MCI‐AD could be a mechanism to counteract the activation of neuroinflammatory processes. It is possible that TREM 2 and ApoE ε4 interact synergistically in the pre‐clinical stage of AD. Therefore, TREM 2 may be useful as an early peripheral biomarker for the development of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ene.13583

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 66

Metadata

Authors
Casati, M., Ferri, E., Gussago, C., Mazzola, P., Abbate, C., Bellelli, G., Mari, D., Cesari, M., & Arosio, B.
Venue
European Journal of Neurology
Publisher
Wiley
Published
2018-03-26
Volume
25
Issue
6
Pages
805-810
ISSN
  • 1351-5101 (ISSN-L)
  • 1468-1331
OpenAlex
W2789326733
Cited by
66
References
17
FWCI
3.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased expression of TREM 2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer's disease. https://app.cochat.ai/papers/10.1111/ene.13583
The paper
Casati, M., Ferri, E., Gussago, C., Mazzola, P., Abbate, C., Bellelli, G., Mari, D., Cesari, M., & Arosio, B. (2018). Increased expression of TREM 2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer's disease. European Journal of Neurology. https://doi.org/10.1111/ene.13583

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.